Low
₹8,931.00
High
₹9,036.50
| Previous Close | ₹8,957.00 |
|---|---|
| Day's Range | ₹8,931.00 - ₹9,036.50 |
| Open | ₹9,025.00 |
| 52 Week Range | ₹6,696.50 - ₹9,036.50 |
| Volume | 2,68,253 |
| Market Cap | ₹0.13 |
| Previous Close | ₹8,955.00 |
|---|---|
| Day's Range | ₹8,937.80 - ₹9,099.95 |
| Open | ₹9,099.95 |
| 52 Week Range | ₹6,680.00 - ₹9,099.95 |
| Volume | 3,037 |
| Market Cap | ₹0.13 |
| Trade Value ( ₹ in Lacs) | 24,053.99 |
|---|---|
| Market Cap (₹ in Mn) | 0.13 |
| Dividend Yield(%) | 0.22 |
| Price/Earning (TTM) | 66.31 |
| TTM EPS (₹) | 135.04 |
| P/E Ratio | 55.01 |
| Book Value(₹) | 13.59 |
| PAT Margin (%) | 7.94 |
| Face Value (₹) | 5.00 |
| ROCE(%) | 21.73 |
| Trade Value ( ₹ in Lacs) | 272.56 |
|---|---|
| Market Cap (₹ in Mn) | 0.13 |
| Dividend Yield(%) | 0.22 |
| Price/Earning (TTM) | 66.31 |
| TTM EPS (₹) | 135.04 |
| P/E Ratio | 55.01 |
| Book Value(₹) | 13.59 |
| PAT Margin (%) | 7.94 |
| Face Value (₹) | 5.00 |
| ROCE(%) | 21.73 |
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 20753.0 | 217940.0 |
| Expenses | N/A | N/A |
| PBT | 4200.0 | 20391.0 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 3334.0 | 15051.0 |
| Founded | 1979 |
|---|---|
| Managing Director | Suneeta Reddy |
| NSE Symbol | APOLLOHOSP |
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,77,311.70 | 1,989.35 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 2,13,878.74 | 8,056.65 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,94,094.11 | 5,130.00 | 3,480.60 - 3,480.60 |
| Apollo Hospitals Enterprise Ltd. | 1,28,759.16 | 8,960.00 | 6,696.50 - 6,696.50 |
| Cipla Ltd. | 1,18,992.73 | 1,473.00 | 1,165.70 - 1,165.70 |
| Zydus Lifesciences Ltd. | 1,12,368.81 | 1,126.50 | 835.50 - 835.50 |
| Lupin Ltd. | 1,10,374.22 | 2,418.30 | 1,836.80 - 1,836.80 |
| Max Healthcare Institute Ltd. | 1,06,918.95 | 1,098.55 | 903.00 - 903.00 |
| Mankind Pharma Ltd. | 1,02,005.88 | 2,469.90 | 1,909.70 - 1,909.70 |
| Laurus Labs Ltd. | 98,126.10 | 1,816.25 | 810.05 - 810.05 |
No Records Found
Pursuant to Regulation 30 and 46 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Apollo Hospitals Enterprise has informed that a conference call for the analysts/investors is scheduled to be held on Thursday, 21st May 2026 at 3.00 pm to discuss the audited financial results of the Company for the quarter and year ended 31st March 2026.
The above information is a part of company’s filings submitted to BSE.
Pursuant to Regulation 30 of the SEBI (listing Obligation and Disclosure Requirement) Regulations, 2015, iStreet Network has informed that the company has received listing approval for 10,83,334 equity shares vide letter LOD/PREF/AP/FIP/591/2026-27 dated July 31, 2026 from BSE issued to non-promoter on preferential basis pursuant to conversion of warrants. The company has enclosed a copy of the Listing Approval of the BSE.
The above information is a part of company’s filings submitted to BSE.
CORONA Remedies has informed the Board of Directors, at its meeting held on Friday, July 31, 2026 had considered and approved the Unaudited Financial Results of the Company (Standalone and Consolidated) for the first quarter and three months ended on June 30, 2026. Pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, it has enclosed the newspaper advertisement of the Unaudited Financial Results, published today in Financial Express (English and Gujarati). The extract of aforesaid newspaper publication is also being made available on the website of the Company at www.coronaremedies.com.
The above information is a part of company’s filings submitted to BSE.
No Records Found
The current share price of Apollo Hospitals Enterprise Ltd. is ₹8,957.00 as of 2026-07-31.
The market capitalisation of Apollo Hospitals Enterprise Ltd. is ₹128,759.16 as of 2026-07-31.
The 1-year return of Apollo Hospitals Enterprise Ltd. is 1,605.50% as of 2026-07-31.
The P/E ratio of Apollo Hospitals Enterprise Ltd. is 55.01 as of 2026-08-02.
The 52-week high and low of Apollo Hospitals Enterprise Ltd. are ₹9,036.50 and ₹6,696.50, respectively, as of 2026-07-31.
Apollo Hospitals Enterprise Limited provides healthcare services including hospital care, pharmacy services, diagnostics, telemedicine, and medical education through a large network of healthcare facilities across India.
Apollo Hospitals Enterprise Limited was founded by Dr. Prathap C. Reddy. As a listed company, its shareholding is distributed among promoters, institutional investors, and public shareholders, as disclosed in its shareholding pattern filed with stock exchanges.
Apollo Hospitals Enterprise Limited was founded in 1983 and is one of the earliest private healthcare providers in India.
The NSE trading symbol of Apollo Hospitals Enterprise Limited is APOLLOHOSP. This symbol is used to identify the company's equity shares on the National Stock Exchange of India.
The headquarters of Apollo Hospitals Enterprise Limited is located in Chennai, Tamil Nadu, India.
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.